Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas

27 Sept 2016

Abstract excerpt

// Małgorzata Czyż 1 , Monika Toma 2 , Anna Gajos-Michniewicz 1 , Kinga Majchrzak 1 , Grazyna Hoser 3 , Janusz Szemraj 4 , Margaret Nieborowska-Skorska 5 , Phil Cheng 6 , Daniel Gritsyuk 5 , Mitchell Levesque 6 , Reinhard Dummer 6 , Tomasz Sliwinski 2 , Tomasz Skorski 5 1 Department of Molecular Biology of Cancer, Medical University of Lodz, 92-215 Lodz, Poland 2 Department of Molecular Genetics, University of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27705909
DOI: 10.18632/oncotarget.12270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomasPMID 27705909Read ↗

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanomaSemantic proximity Read ↗

PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to AchieveSemantic proximity Read ↗

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?Semantic proximity Read ↗

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma TreatmentSemantic proximity Read ↗

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In VivoSemantic proximity Read ↗

Breast Cancer Predisposition Genes and Synthetic Lethality.Semantic proximity Read ↗

Homologous Recombination Deficiency (HRD) in Cutaneous OncologySemantic proximity Read ↗

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.Semantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanomaSemantic proximity Read ↗

PARP inhibition as a prototype for synthetic lethal screens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.